Old Web
English
Sign In
Acemap
>
authorDetail
>
Olivier Favre-Bulle
Olivier Favre-Bulle
French Institute of Health and Medical Research
Biology
Biochemistry
GPVI
Pharmacology
Glycoprotein
4
Papers
93
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab: First-in-Human Healthy Volunteer Trial
2019
Arteriosclerosis, Thrombosis, and Vascular Biology
Christine Voors-Pette
Kristell Lebozec
Peter Dogterom
Laurie Jullien
Philippe Billiald
Pauline Ferlan
Lionel Renaud
Olivier Favre-Bulle
Gilles Avenard
Matthias Machacek
Yannick Pletan
Martine Jandrot-Perrus
Show All
Source
Cite
Save
Citations (2)
Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab
2018
Arteriosclerosis, Thrombosis, and Vascular Biology
Christine Voors-Pette
Kristell Lebozec
Peter Dogterom
Laurie Jullien
Philippe Billiald
Pauline Ferlan
Lionel Renaud
Olivier Favre-Bulle
Gilles Avenard
Matthias Machacek
Yannick Pletan
Martine Jandrot-Perrus
Show All
Source
Cite
Save
Citations (38)
Quality and cost assessment of a recombinant antibody fragment produced from mammalian, yeast and prokaryotic host cells: A case study prior to pharmaceutical development
2018
New Biotechnology
Kristell Lebozec
Martine Jandrot-Perrus
Gilles Avenard
Olivier Favre-Bulle
Philippe Billiald
Show All
Source
Cite
Save
Citations (18)
Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risks.
2017
mAbs
Kristell Lebozec
Martine Jandrot-Perrus
Gilles Avenard
Olivier Favre-Bulle
Philippe Billiald
Show All
Source
Cite
Save
Citations (35)
1